Minnesota-based ANI Pharmaceuticals, Inc. announced that it has acquired U.S. rights to market Atacand HCT, Arimdex and Casodex from AstraZeneca for $46.5 million in cash, royalties, and sales-based milestones.
AstraZeneca will continue to market and supply the drugs outside the U.S.
The products generated approximately $19 million in U.S. market sales during the trailing twelve months through October 2017, according to IMS Health.
Arthur S. Przybyl, ANI’s President and CEO stated, “This acquisition complements our brand and generic strategies and further expands and diversifies our commercial portfolio. Importantly, ANI has the capability to manufacture and package all of the products at our containment facility in Baudette, MN.”
The drugs are used for the treatment of high blood pressure and breast cancer.
AstraZeneca has been selling off product lines as it focus on rebuilding a drug pipeline that has been hit by mainstays losing patent protection. At last report, the company has 1,500 employees in Delaware.